Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247994 | 0.68 | MAOA (0.41) | TDP1SMN1; SMN2PARP1MAOAMAOB | |
| SCHEMBL15724650 | 0.68 | TDP1 (0.56) | TDP1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL10696856 | 0.68 | TDP1 (0.56) | TDP1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3487104 | 0.68 | MAOA (0.41) | TDP1SMN1; SMN2PARP1MAOAMAOB | |
| SCHEMBL9983116 | 0.67 | EZH2 (0.38) | TDP1PARP1MAOAMAOB | |
| SCHEMBL18768108 | 0.67 | AKR1B1 (0.43) | PARP1MAOAMAOB | |
| SCHEMBL12036044 | 0.66 | MAOA (0.40) | TDP1PARP1ALDH1A1MAOAMAOB | |
| SCHEMBL3047514 | 0.64 | USP2 (0.35) | — | |
| SCHEMBL13799419 | 0.64 | AKR1B1 (0.44) | TDP1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL18751317 | 0.63 | EZH2 (0.41) | TDP1PARP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989481-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | claimed |
| US-7605174-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-20 | — | — | US | claimed |
| EP-1888547-A1 | INDANE DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-20 | — | — | EP | claimed |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-24 | — | — | US | claimed |
| WO-2006133459-A1 | INDANE DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-12-14 | — | — | WO | claimed |
| US-7989481-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090326023-A1 | Indane Derivatives as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| US-7605174-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326023-A1 | Indane Derivatives as Modulators of ION Channels | KCNJ2, TRPV1, KCNJ1 | TDP1 3291/4885SMN1; SMN2 1301/4885PARP1 3998/4885 |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | KCNJ2, TRPV1, KCNJ1 | TDP1 3514/4885SMN1; SMN2 1255/4885PARP1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.